Tests SUN-627 for safety in people with progressive multiple sclerosis
Tests SUN-627 against a placebo in adults with non-active progressive multiple sclerosis.
Plain-language title generated from the registry record
Registry title: A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
Key facts
- Where
- Atlanta, Columbus, Dallas, Oklahoma City, Raleigh, Stony Brook, and Tampa, United StatesSee the 7 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07840326, who can take part
Where in United States
- Local Institution - Site 102Atlanta, United StatesTaking people
- Local Institution - Site 104Columbus, United StatesTaking people
- Local Institution - Site 107Dallas, United StatesNot yet recruiting
- Local Institution - Site 105Oklahoma City, United StatesTaking people
- Local Institution - Site 101Raleigh, United StatesTaking people
- Local Institution - Site 106Stony Brook, United StatesNot yet recruiting
- Local Institution - Site 103Tampa, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sundance Biosciences, Inc.
- Trial code
- NCT07840326
- Record updated
- 30 October 2026
- Original description
The goal of this Phase 2 clinical trial is to investigate the safety and tolerability of SUN-627 in men and women aged 18-70 years old with a diagnosis of non-active SPMS/PPMS.Read full original descriptionShow less
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)
The goal of this Phase 2 clinical trial is to investigate the safety and tolerability of SUN-627 in men and women aged 18-70 years old with a diagnosis of non-active SPMS/PPMS.
Inclusion: Aged 18-70, inclusive; Diagnosis of PPMS or non-active SPMS; No MS relapses in the past 2 years; Evidence that MS has continued to get worse over time; A level of disability that fits the study requirements.
Exclusion: Use of certain medications or treatments before the study, or need for these treatments during the study; Certain abnormal heart rhythm findings on ECG or other heart conditions that may increase risk; Certain serious or unstable medical conditions that could make the study unsafe; Active infection, recent infection, or a history of repeated infections; Additional inclusion and exclusion criteria are outlined in the full study protocol; Current participation in another research study.